"The Prix Galien is about honouring excellence in pharmaceutical research and development and it is about recognising the contribution that new medicines make to the public health. The judging panel has been impressed by the creativity, innovation and scientific rigour that has gone into these new medicines."
- Professor Sir Michael Rawlins, Chairman of NICE and chair of the judging panel
| 
The Novartis treatment for patients with severe, persistent allergic asthma has been awarded a prestigious Prix Galien award for innovative research and development. Unlike other asthma therapies, the treatment is an antibody that targets one of the underlying causes of the allergic inflammatory cascade that drives the onset of asthma attacks and symptoms. This internationally recognised award, announced at a ceremony at the House of Commons in September 2006, is recognition of outstanding achievement in research and development by Novartis.
